UNSPSC 51203102: Ecallantide

This classification denotes a protease inhibitor, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 5Q6TZN2HNM. European Medicines Agency schedules Ecallantide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB31283. Ecallantide generally arises in the molecular formula C305H442N88O91S8.

The term ECALLANTIDE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 20, No. 1, 2006, list 55.) Most nations, for tariff and trade purposes, schedule ecallantide under HS 29349990 and SITC 51579. As of Q4 2014, ECALLANTIDE remains US FDA's Preferred Term for this commodity. Ecallantide bears US NLM identifiers UMLS ID C1722685 and NCI Concept Code C65505.

UNSPSC 51203102 Ecallantide, a Commodity code, reflects state and local procurement of pharmaceutical products and medical supplies used in emergency response and public health initiatives. Recent opportunities tagged under this code show state and local health departments and county governments purchasing naloxone, antibiotic medications, and drug deactivation systems through piggyback contracts and competitive bidding processes. The Illinois Department of Public Health awarded a pharmaceutical warehouse contract through the MMCAP Infuse consortium to supply Doxycycline Hyclate and Ciprofloxacin Hydrochloride tablets over a three-year term with renewal options, while Seminole County, Florida solicited naloxone and safe drug deactivation systems for community health initiatives. Issuing bodies include state health departments and county health and community services agencies; recent activity shows repeat purchasing patterns through both cooperative purchasing vehicles and direct competitive procurement.

Geographic activity centers on Illinois and Florida based on recent solicitations. The Illinois Department of Public Health awarded a $2,999,999.11 contract over the life of the agreement (IFB 26482DPHPREPDB53392, completed August 28, 2026) for pharmaceutical warehouse stock through piggyback procurement. Seminole County, Florida issued an IFB (IFB60459723LAS, posted June 30, 2026, due July 26, 2023) for 1,900 units of naloxone and 800 safe drug deactivation systems annually on a two-year initial term with one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Both procurements required vendors to absorb shipping and delivery costs and comply with standard workplace certifications and E-Verify requirements.